Telo Genomics (TSXV:TELO) ROCE % : -275.03% (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Telo Genomics's annualized ROCE % for the quarter that ended in Dec. 2024 was -275.03%.

Telo Genomics ROCE % Historical Data

The historical data trend for Telo Genomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics ROCE % Chart

Telo Genomics Annual Data

Trend

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-55.36

-66.27

-106.67

-168.29

Telo Genomics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-205.54	-268.12	-402.69	-705.58	-275.03

Telo Genomics ROCE % Calculation

Telo Genomics's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-2.723	/	( ( (2.926 - 0.28)	+	(0.966 - 0.376) )	/ 2 )
	=	-2.723	/	( (2.646	+	0.59)	/ 2 )
	=	-2.723	/	1.618
	=	-168.29 %

Telo Genomics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-2.456	/	( ( (0.44 - 0.403)	+	(2.353 - 0.604) )	/ 2 )
	=	-2.456	/	( ( 0.037	+	1.749 )	/ 2 )
	=	-2.456	/	0.893
	=	-275.03 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Telo Genomics (TSXV:TELO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Telo Genomics ROCE % Related Terms

Thank you for viewing the detailed overview of Telo Genomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TDSGF:USA

Address

101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7

Website

https://www.telodx.com

Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.

Executives